Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George I Papakostas, M.D.

Co-Author

This page shows the publications co-authored by George Papakostas and David Mischoulon.
Connection Strength

6.287
  1. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017 04; 78(4):449-455.
    View in: PubMed
    Score: 0.725
  2. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012 Jun; 73(6):843-8.
    View in: PubMed
    Score: 0.517
  3. Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. Front Psychiatry. 2018; 9:424.
    View in: PubMed
    Score: 0.200
  4. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.187
  5. Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial. Pharmacopsychiatry. 2015 Jul; 48(4-5):141-4.
    View in: PubMed
    Score: 0.159
  6. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015 Mar; 62:56-61.
    View in: PubMed
    Score: 0.156
  7. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9.
    View in: PubMed
    Score: 0.154
  8. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Int Clin Psychopharmacol. 2014 Nov; 29(6):332-8.
    View in: PubMed
    Score: 0.153
  9. Dr. Mischoulon and colleagues reply. J Clin Psychiatry. 2014 Nov; 75(11):e1328-9.
    View in: PubMed
    Score: 0.153
  10. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014 Apr; 75(4):370-6.
    View in: PubMed
    Score: 0.147
  11. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014 Aug; 164:76-81.
    View in: PubMed
    Score: 0.147
  12. Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety. 2013 Sep; 30(9):873-80.
    View in: PubMed
    Score: 0.139
  13. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74.
    View in: PubMed
    Score: 0.134
  14. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7.
    View in: PubMed
    Score: 0.134
  15. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86.
    View in: PubMed
    Score: 0.130
  16. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011 Dec; 72(12):1669-76.
    View in: PubMed
    Score: 0.124
  17. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
    View in: PubMed
    Score: 0.124
  18. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012 Feb; 136(3):1174-8.
    View in: PubMed
    Score: 0.123
  19. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2012 Oct; 27(7):518-21.
    View in: PubMed
    Score: 0.121
  20. SAMe and sexual functioning. Eur Psychiatry. 2012 Aug; 27(6):451-4.
    View in: PubMed
    Score: 0.119
  21. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21.
    View in: PubMed
    Score: 0.114
  22. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010 Jul; 25(4):214-7.
    View in: PubMed
    Score: 0.113
  23. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug; 167(8):942-8.
    View in: PubMed
    Score: 0.113
  24. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
    View in: PubMed
    Score: 0.113
  25. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009 Dec; 70(12):1636-44.
    View in: PubMed
    Score: 0.107
  26. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5.
    View in: PubMed
    Score: 0.102
  27. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008 Oct 30; 161(1):116-20.
    View in: PubMed
    Score: 0.100
  28. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 Sep; 18(9):639-45.
    View in: PubMed
    Score: 0.098
  29. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008; 14(3):182-91.
    View in: PubMed
    Score: 0.095
  30. Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Hum Psychopharmacol. 2006 Jun; 21(4):221-5.
    View in: PubMed
    Score: 0.086
  31. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 23(3):178-81.
    View in: PubMed
    Score: 0.083
  32. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
    Score: 0.079
  33. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
    Score: 0.075
  34. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
    Score: 0.075
  35. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004 Mar; 14(2):135-42.
    View in: PubMed
    Score: 0.073
  36. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7.
    View in: PubMed
    Score: 0.072
  37. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
    Score: 0.069
  38. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50.
    View in: PubMed
    Score: 0.067
  39. Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. J Psychiatr Res. 2021 01; 133:73-81.
    View in: PubMed
    Score: 0.058
  40. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 10 01; 177(10):965-973.
    View in: PubMed
    Score: 0.057
  41. Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. Compr Psychiatry. 2019 11; 95:152140.
    View in: PubMed
    Score: 0.054
  42. Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. J Affect Disord. 2019 12 01; 259:349-354.
    View in: PubMed
    Score: 0.053
  43. Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder. Sci Rep. 2019 05 16; 9(1):7462.
    View in: PubMed
    Score: 0.052
  44. Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. J Affect Disord. 2019 03 01; 246:157-165.
    View in: PubMed
    Score: 0.051
  45. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497.
    View in: PubMed
    Score: 0.051
  46. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Focus (Am Psychiatr Publ). 2018 Jul; 16(3):328-340.
    View in: PubMed
    Score: 0.050
  47. Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder. Sci Rep. 2017 Nov 17; 7(1):15772.
    View in: PubMed
    Score: 0.047
  48. Effects of smartphone use with and without blue light at night inĀ healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. J Psychiatr Res. 2017 04; 87:61-70.
    View in: PubMed
    Score: 0.044
  49. Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder. Transl Psychiatry. 2016 06 07; 6(6):e835.
    View in: PubMed
    Score: 0.043
  50. Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. Psychiatry Investig. 2016 May; 13(3):321-6.
    View in: PubMed
    Score: 0.043
  51. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry. 2016 Jun 01; 173(6):575-87.
    View in: PubMed
    Score: 0.042
  52. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. J Affect Disord. 2015 Oct 01; 185:24-30.
    View in: PubMed
    Score: 0.040
  53. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010 Aug; 22(3):166-71.
    View in: PubMed
    Score: 0.029
  54. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009 Dec; 14(12):688-94.
    View in: PubMed
    Score: 0.027
  55. Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry. 2006 Aug 01; 60(3):270-4.
    View in: PubMed
    Score: 0.021
  56. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42.
    View in: PubMed
    Score: 0.020
  57. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.